Sanofi Pasteur, 14 Espace Henry Vallée, 69007, Lyon, France.
IQVIA, 92400, Courbevoie, France.
BMC Infect Dis. 2021 Aug 2;21(1):730. doi: 10.1186/s12879-021-06399-8.
Respiratory syncytial virus (RSV) is the main cause of infant and child hospitalizations. The study objective is to estimate the RSV-associated hospitalizations and economic burden in young children in France to inform future preventive strategies.
We conducted a retrospective analysis of RSV-associated hospitalizations data from the French Hospital database (PMSI-MCO) which covers the entire French population. All children aged < 5 years hospitalized with RSV ICD-10 codes (J210, J219, J45, J121, J205, R062) from 2010 to 2018, were included. Descriptive analyses were conducted by RSV seasons (Oct to March), by respiratory years (July to June) and per age groups.
On average 45,225 RSV-associated hospitalizations (range: 43,715 - 54,616) per season was reported in France, 69% among children < 1 year old. This represents 28% of all-cause hospitalizations that occurred among children < 1 year old, and less than 10% of all-cause hospitalizations in older children. Number of RSV-associated hospitalizations were similar for infants born during (Oct-March) or outside (April-September) their first RSV season. The highest risk being reported for infants born from September through November. The associated hospitalization cost increased between 2010 - 11 and 2017-18, from €93.2 million to €124.1 million, respectively, and infants < 1 year old represented 80% of the economic burden.
RSV is an important cause of child hospitalization in France. The burden on healthcare system is mainly driven by < 1 year olds, and preventive strategies should be implemented before the first RSV season.
呼吸道合胞病毒(RSV)是导致婴儿和儿童住院的主要原因。本研究旨在评估法国幼童中 RSV 相关住院治疗情况和经济负担,为未来的预防策略提供信息。
我们对法国医院数据库(PMSI-MCO)中与 RSV 相关的住院治疗数据进行了回顾性分析,该数据库覆盖了法国的全部人口。所有在 2010 年至 2018 年期间因 RSV ICD-10 编码(J210、J219、J45、J121、J205、R062)住院的<5 岁儿童均纳入研究。通过 RSV 季节(10 月至 3 月)、呼吸年(7 月至 6 月)和年龄组进行描述性分析。
法国平均每个季节报告有 45,225 例 RSV 相关住院治疗(范围:43,715-54,616),其中 69%为<1 岁的儿童。这占<1 岁儿童所有因病因住院治疗的 28%,不到大龄儿童所有因病因住院治疗的 10%。在其第一个 RSV 季节出生的婴儿和不在该季节出生的婴儿,其 RSV 相关住院治疗数量相似。报告的最高风险发生在 9 月至 11 月出生的婴儿。2010-11 年至 2017-18 年,与 RSV 相关的住院治疗费用从 9320 万欧元增加到 1.241 亿欧元,<1 岁的婴儿占经济负担的 80%。
RSV 是法国儿童住院的重要原因。医疗系统的负担主要由<1 岁的婴儿承担,应在第一个 RSV 季节之前实施预防策略。